Nature Communications · 2015 · 1.2K citations · 53 references
Life SciencesCell BiologyImmunologyCellular MetabolismImmunotherapyMetabolismFatty Acid MetabolismImmune Checkpoint InhibitorsImmune Checkpoint RegulationLipid MetabolismMetabolic ReprogrammingT Cell BiologyCellular Metabolic ReprogrammingEffector T Cell DifferentiationEffector T Cell MetabolismGlycolysisGlycolysis In Immune CellsMetabolic Regulation Of T Cell DifferentiationPd-1 SignalingProgrammed Cell Death Protein 1 (Pd-1) Pathway
T cells reprogram metabolism upon activation, shaping their functional fates. PD‑1 engagement suppresses glycolysis and amino‑acid metabolism while boosting fatty‑acid oxidation and lipolysis, thereby hindering effector differentiation yet promoting T‑cell persistence and responsiveness to PD‑1 blockade.
During activation, T cells undergo metabolic reprogramming, which imprints distinct functional fates. We determined that on PD-1 ligation, activated T cells are unable to engage in glycolysis or amino acid metabolism but have an increased rate of fatty acid β-oxidation (FAO). PD-1 promotes FAO of endogenous lipids by increasing expression of CPT1A, and inducing lipolysis as indicated by elevation of the lipase ATGL, the lipolysis marker glycerol and release of fatty acids. Conversely, CTLA-4 inhibits glycolysis without augmenting FAO, suggesting that CTLA-4 sustains the metabolic profile of non-activated cells. Because T cells utilize glycolysis during differentiation to effectors, our findings reveal a metabolic mechanism responsible for PD-1-mediated blockade of T-effector cell differentiation. The enhancement of FAO provides a mechanistic explanation for the longevity of T cells receiving PD-1 signals in patients with chronic infections and cancer, and for their capacity to be reinvigorated by PD-1 blockade.
53
Restoring function in exhausted CD8 T cells during chronic viral infection
Daniel L. Barber, E. John Wherry, David Masopust et al. · Nature · 2005 · 4K citations
On Respiratory Impairment in Cancer Cells
Otto Warbürg · Science · 1956 · 3.2K citations
Medicine, Cancer Biology, Oncology +13
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman, Clive R. Wood, Tatyana Chernova et al. · Nature Immunology · 2001 · 2.9K citations
Julie St‐Pierre, Stavit Drori, Marc Uldry et al. · Cell · 2006 · 2.2K citations · Full text